Zydus Life Science , a prominent player in the pharmaceutical industry, has announced the passing of Mr. Samir Desai, President-BU Biologics and a key member of the company's senior management. The company informed the stock exchanges BSE and NSE about this development on August 26, 2025.

Senior Management Change

Mr. Samir Desai, who held the position of President-BU Biologics at Zydus Lifesciences, passed away on August 26, 2025. As a result, he ceases to be part of the company's senior management team. The company expressed profound grief in its communication to the stock exchanges.

In compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Zydus Lifesciences provided the necessary details regarding this change in senior management.

Enhanced ESG Rating Performance

Zydus Lifesciences has received an improved Environmental, Social, and Governance (ESG) score for the financial year 2024-2025. SES ESG Research Private Limited has assigned the company an ESG score of 69.4, representing an improvement from the previous year's score of 67.8.

According to the rating framework, a score ranging between 60-70 is categorized as Medium Risk. The company noted that this rating was unsolicited, indicating an independent assessment of its ESG practices.

Regulatory Compliance and Disclosure

Dhaval N. Soni, Company Secretary and Compliance Officer of Zydus Lifesciences, signed the communications to the stock exchanges. The ESG rating disclosure was made in compliance with Regulation 30 of the Listing Regulations, read with SEBI Circulars dated November 11, 2024, and December 31, 2024.

The company ensured timely disclosure of these significant events, maintaining transparency with its stakeholders and complying with regulatory requirements. While Zydus Lifesciences faces the challenge of losing a key member of its senior management team, the improved ESG score indicates the company's ongoing efforts to enhance its sustainability and governance practices.

Zydus Lifesciences , a leading pharmaceutical company, has reported a solid start to the fiscal year, with consolidated revenues reaching ₹65.70 billion in the first quarter, marking a 6% year-on-year growth. The company's financial performance for the quarter ended June 30 showcases its resilience and strategic focus across various business segments.

Financial Highlights

• Consolidated revenues: ₹65.70 billion, up 6% year-on-year
• EBITDA: ₹20.90 billion, with a strong margin of 31.8%
• Net profit: ₹14.70 billion, increasing 3% year-on-year
• Net cash position: Strengthened to ₹56.30 billion from ₹48.80 billion in the previous quarter

Business Segment Performance

US Formulations

• Revenue: ₹31.80 billion, growing 3% year-on-year and 2% quarter-on-quarter
• Filed 3 ANDAs, received 6 approvals, and launched 3 new products

India Geography

• Overall growth: 6% year-on-year
• Branded formulations: Outpaced market growth at 9% year-on-year
• Consumer Wellness: ₹8.50 billion, up 2% year-on-year

International Markets

• Formulations business: ₹7.30 billion, with strong 37% year-on-year growth

Strategic Developments

1. Amplitude Surgical Acquisition: Completed acquisition of 85.6% stake, marking entry into the orthopedic implant space for knee and hip, with navigation and robotic capabilities.

2. Braile Biomedica Partnership: Entered strategic partnership for exclusive commercialization of TAVI (Transcatheter Aortic Valve Implantation) technology across Europe, India, and select markets.

3. US-based Biological Manufacturing Facility: Planned acquisition of Agenus Inc.'s facility, marking entry into global biologics CDMO business.

4. R&D Progress:

   • Initiated Phase II(b) clinical trial of Usnoflast for ALS in the US
   • Received market authorization approvals for rituximab and aflibercept biosimilars
   • Completed Phase II clinical trial of Hepatitis E vaccine

Management Commentary

Dr. Sharvil Patel, Managing Director of Zydus Lifesciences, commented on the results: "We had a steady start to the fiscal year. All our businesses maintained the growth momentum with robust operating profitability and performed in line with expectations except for a couple of summer-oriented brands in the Consumer Wellness business, which faced seasonal challenges."

He added, "We stay committed to achieve our targeted top line growth and profitability for the current financial year. This will be driven by our strategic intent of going beyond the pill to address diverse healthcare needs of the patients and also superior execution."

Outlook

• The company maintains its guidance of single-digit growth in the US market for the fiscal year.
• International markets are expected to deliver strong double-digit growth in the high teens to mid-twenties range.
• Management expects EBITDA margins to remain above 26% for the fiscal year.

Zydus Lifesciences continues to focus on expanding its presence across targeted therapeutic areas, leveraging its diverse portfolio of innovative products, and driving growth through strategic initiatives in key markets. With a strong pipeline of products and ongoing R&D efforts, the company is well-positioned to sustain its growth trajectory in the coming quarters.